Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 17/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 16/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20230159 | 0.90 | OPRM1 (0.82) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20213021 | 0.88 | OPRM1 (0.78) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20213020 | 0.88 | OPRM1 (0.78) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL21179732 | 0.88 | OPRM1 (0.78) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20230160 | 0.88 | OPRM1 (0.78) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20229793 | 0.87 | OPRM1 (0.77) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20542575 | 0.87 | OPRM1 (0.77) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL30677515 | 0.87 | OPRM1 (0.77) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20212895 | 0.87 | OPRM1 (0.77) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL18920972 | 0.87 | OPRM1 (0.77) | OPRM1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-19 | — | — | US | claimed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | claimed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | claimed |
| EP-1598338-B9 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | EP | claimed |
| EP-1598338-B1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | claimed |
| EP-1918279-A2 | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-05-07 | — | — | EP | claimed |
| EP-1598338-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | claimed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | claimed |
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-19 | — | — | US | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1598338-B9 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | EP | disclosed |
| EP-1379246-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-09-28 | — | — | EP | disclosed |
| US-20050159452-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2005-07-21 | — | — | US | disclosed |
| US-6867222-B2 | Nociceptin analogs | EURO-CELTIQUE, S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| EP-1379246-A1 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | disclosed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | OPRM1 8/4885OPRL1 1/4885OPRK1 5/4885 |
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRL1 1/4885OPRK1 3/4885 |
| US-20030069249-A1 | Nociceptin analogs | OPRL1, NPY1R, OPRK1 | OPRM1 4/4885OPRL1 1/4885OPRK1 3/4885 |
| US-20050159452-A1 | Nociceptin analogs | OPRL1, NPY1R, NPBWR1 | OPRM1 8/4885OPRL1 1/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.